Back to top
more

Legend Biotech (LEGN)

(Real Time Quote from BATS)

$46.20 USD

46.20
548,186

-0.92 (-1.95%)

Updated Apr 19, 2024 01:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

FDA Expands J&J's (JNJ) Carvykti Label in Multiple Myeloma

by Zacks Equity Research

Following the label expansion, J&J's (JNJ) Carvykti is approved as a second-line treatment for adults with relapsed/refractory myeloma. It was initially approved for use as a fifth- or later-line treatment.

Kaibalya Pravo Dey headshot

Why Legend Biotech (LEGN) Stock Might be a Great Pick

by Kaibalya Pravo Dey

Legend Biotech (LEGN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Company News for Mar 12, 2024

by Zacks Equity Research

Companies in The News Are: LEGN, BA, ALK, FTRE, AVGO.

The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys

by Zacks Equity Research

Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys are part of the Zacks top Analyst Blog.

Nalak Das headshot

5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024

by Nalak Das

We have narrowed our search to five biotech stocks with strong potential for 2024. These are MOR, LEGN, ASND, EXEL and EXAS.

Ekta Bagri headshot

FDA Demands "Boxed Warning" to CAR T-Cell Therapy Labels

by Ekta Bagri

The FDA directs companies like NVS, BMY, GILD and others to add "boxed warning" to the labels of their CAR T-cell immunotherapies after it identified adverse events.

Ekta Bagri headshot

CAR T-Cell Therapies Under FDA Watch on Reports of Malignancies

by Ekta Bagri

The FDA has undertaken an investigation of T-cell malignancies in patients undergoing CAR T-cell therapy treatment. Therapies from NVS, BMY and GILD are under the spotlight.

The Zacks Analyst Blog Highlights Gilead Sciences, Legend Biotech, BeiGene, Exact Sciences and Sarepta Therapeutics

by Zacks Equity Research

Gilead Sciences, Legend Biotech, BeiGene, Exact Sciences and Sarepta Therapeutics are part of the Zacks top Analyst Blog.

Nalak Das headshot

5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024

by Nalak Das

We have narrowed our search to five biotech stocks with strong potential for 2024. These are: LEGN, BGNE, GILD, EXAS, SRPT.

Will Top-Line Decline Hurt Keysight's (KEYS) Q4 Earnings?

by Zacks Equity Research

Keysight (KEYS) is expected to report a top line contraction year over year, owing to weakness in some consumer electronic markets stemming from inventory adjustments and macroeconomic headwinds.

Should You Buy Legend Biotech (LEGN) Ahead of Earnings?

by Zacks Equity Research

Legend Biotech (LEGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Ekta Bagri headshot

4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates

by Ekta Bagri

Let us look at a few biotech companies, ACLX, LEGN, GRCL and EYEN, which are poised to beat third-quarter earnings estimates.

Will Revenue Growth Boost Keysight's (KEYS) Q3 Earnings?

by Zacks Equity Research

Keysight (KEYS) is expected to report higher revenues year over year in the third quarter of fiscal 2023, backed by a strong emphasis on innovation and rising demand for its electronic design and test solutions.

Why Earnings Season Could Be Great for Legend Biotech (LEGN)

by Zacks Equity Research

Legend Biotech (LEGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Ekta Bagri headshot

3 Biotech Stocks Poised to Beat Q2 Earnings Estimates

by Ekta Bagri

We look at a few biotech companies, LEGN, KOD, GRTX, which are poised to beat second-quarter earnings estimates.

Nalak Das headshot

Top 5 Stocks Set to Beat on Earnings Next Week

by Nalak Das

We have narrowed our search to five stocks that are set to declare earnings results next week. These are: LEGN, TJX, WMT, ONON, BILL.

Will Top-line Expansion Boost Akamai (AKAM) Q2 Earnings?

by Zacks Equity Research

Akamai (AKAM) is expected to report higher revenues year over year in the second quarter of 2023, driven by positive demand trends in the compute and security verticals.

Legend (LEGN) Up 4% on sNDA Submission for Carvykti Expanded Use

by Zacks Equity Research

Legend (LEGN) announces regulatory submission for expanded use of Carvykti to include adult patients with relapsed and lenalidomide-refractory multiple myeloma. Stock rises 4% following the news.

Voyager Therapeutics (VYGR) Surges 11.1%: Is This an Indication of Further Gains?

by Zacks Equity Research

Voyager Therapeutics (VYGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Legend (LEGN) Stock Up 20% on Data Leak From Blood Cancer Study

by Zacks Equity Research

Leaked data from Legend Biotech's (LEGN) phase III study of the blood cancer drug, Carvykti, shows a 74% reduction in risk of death or tumor progression. Stock jumps 20% following the news.

Legend Biotech Corporation Sponsored ADR (LEGN) Soars 19.6%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Legend Biotech Corporation Sponsored ADR (LEGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Legend's (LEGN) Q3 Carvykti Preliminary Sales Top Expectations

by Zacks Equity Research

Legend Biotech (LEGN) reports $55 million as preliminary sales figures for its multiple myeloma therapy in third-quarter 2022. Shares rise 14.2% post the announcement.

Legend Biotech Corporation Sponsored ADR (LEGN) Stock Jumps 14.2%: Will It Continue to Soar?

by Zacks Equity Research

Legend Biotech Corporation Sponsored ADR (LEGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Should You Buy Legend Biotech (LEGN) Ahead of Earnings?

by Zacks Equity Research

Legend Biotech (LEGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Legend Biotech Corporation Sponsored ADR (LEGN) Soars 10.9%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Legend Biotech Corporation Sponsored ADR (LEGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.